Clearside Biomedical, Inc. (CLSD)Â
NASDAQ$1.05+0.04 (3.94%)
Market Cap
$76.98M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
234 of 919
Rank in Industry
136 of 523
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CLSD Insider Trading Activity
CLSD Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $215,110 | 6 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Gibney Anthony S | director | 2 | $129,665 | 0 | $0 | $129,665 |
| Chong Ngai Hang Victor | Chief Medical Officer | 2 | $61,410 | 0 | $0 | $61,410 |
| Thorp Clay | director | 1 | $13,800 | 0 | $0 | $13,800 |
| YERXA BENJAMIN R | director | 1 | $10,235 | 0 | $0 | $10,235 |
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Insider Activity of Clearside Biomedical, Inc.
Over the last 12 months, insiders at Clearside Biomedical, Inc. have bought $215,110 and sold $0 worth of Clearside Biomedical, Inc. stock.
On average, over the past 5 years, insiders at Clearside Biomedical, Inc. have bought $613,935 and sold $872,208 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Gibney Anthony S (director) — $129,665. Chong Ngai Hang Victor (Chief Medical Officer) — $61,410. Thorp Clay (director) — $13,800.
The last purchase of 15,000 shares for transaction amount of $13,800 was made by Thorp Clay (director) on 2025‑02‑24.
List of Insider Buy and Sell Transactions, Clearside Biomedical, Inc.
| 2025-02-24 | Thorp Clay | director | 15,000 0.0192% | $0.92 | $13,800 | +1.14% | ||
| 2024-11-01 | Chong Ngai Hang Victor | Chief Medical Officer | 36,500 0.0483% | $1.00 | $36,500 | -1.62% | ||
| 2024-06-24 | Chong Ngai Hang Victor | Chief Medical Officer | 23,500 0.0309% | $1.06 | $24,910 | -2.78% | ||
| 2024-05-15 | YERXA BENJAMIN R | director | 7,813 0.0104% | $1.31 | $10,235 | -18.94% | ||
| 2024-04-18 | Gibney Anthony S | director | 93,290 0.123% | $1.30 | $121,277 | -18.18% | ||
| 2024-04-17 | Gibney Anthony S | director | 6,710 0.0089% | $1.25 | $8,388 | -13.89% | ||
| 2024-03-20 | Chong Ngai Hang Victor | CHIEF MEDICAL OFFICER | 30,000 0.0394% | $1.60 | $48,000 | -31.90% | ||
| 2024-02-07 | WHITMORE BRADFORD T | 10 percent owner | 444,444 0.7241% | $1.35 | $599,999 | -13.77% | ||
| 2024-01-19 | Sale | LASEZKAY GEORGE M | CEO | 18,000 0.0286% | $1.27 | $22,860 | -5.43% | |
| 2024-01-19 | Sale | Deignan Charles A. | Chief Financial Officer | 12,900 0.0207% | $1.28 | $16,512 | -5.43% | |
| 2023-11-01 | WHITMORE BRADFORD T | 10 percent owner | 64,366 0.101% | $0.74 | $47,901 | +62.52% | ||
| 2023-10-31 | WHITMORE BRADFORD T | 10 percent owner | 70,812 0.1147% | $0.73 | $51,537 | +71.13% | ||
| 2023-10-30 | WHITMORE BRADFORD T | 10 percent owner | 600 0.001% | $0.69 | $411 | +79.97% | ||
| 2023-10-03 | Hutson Nancy J | director | 10,000 0.0159% | $0.86 | $8,600 | +44.88% | ||
| 2023-09-25 | Thorp Clay | director | 10,000 0.0163% | $0.86 | $8,600 | +43.53% | ||
| 2023-01-20 | Sale | Ciulla Thomas | Chief Medical Officer | 13,700 0.0223% | $1.47 | $20,139 | -28.67% | |
| 2023-01-19 | Sale | LASEZKAY GEORGE M | CEO | 20,030 0.033% | $1.46 | $29,244 | -27.21% | |
| 2023-01-19 | Sale | Deignan Charles A. | Chief Financial Officer | 14,030 0.0238% | $1.50 | $21,045 | -27.21% | |
| 2023-01-10 | Sale | Ciulla Thomas | Chief Medical Officer | 2,170 0.0035% | $1.62 | $3,515 | -35.54% | |
| 2022-12-21 | Thorp Clay | director | 14,000 0.0236% | $1.02 | $14,266 | +7.00% |
Total: 132
*Gray background shows transactions not older than one year
Insider Historical Profitability
28.41%
| Thorp Clay | director | 176141 0.2322% | $178,783.12 | 5 | 41 | +11.66% |
| Gibney Anthony S | director | 100000 0.1319% | $101,500.00 | 2 | 0 | |
| Chong Ngai Hang Victor | Chief Medical Officer | 100000 0.1319% | $101,500.00 | 3 | 0 | <0.0001% |
| YERXA BENJAMIN R | director | 17957 0.0237% | $18,226.36 | 1 | 0 | |
| WHITMORE BRADFORD T | 10 percent owner | 4495034 5.9267% | $4.56M | 11 | 3 | +69.04% |
| Hatteras Venture Advisors IV SBIC, LLC | 10 percent owner | 2060514 2.7168% | $2.09M | 1 | 4 | +13.15% |
| Hatteras Venture Advisors III, LLC | 10 percent owner | 1757719 2.3176% | $1.78M | 1 | 4 | +13.15% |
| RMI Investments S.a.r.l. | 10 percent owner | 1558024 2.0543% | $1.58M | 1 | 0 | +13.15% |
| White Daniel H. | President and CEO | 483335 0.6373% | $490,585.03 | 1 | 13 | |
| LASEZKAY GEORGE M | CEO | 466577 0.6152% | $473,575.66 | 1 | 11 | +58.62% |
| Deignan Charles A. | Chief Financial Officer | 384662 0.5072% | $390,431.93 | 4 | 7 | +20.35% |
| Ciulla Thomas | Chief Medical Officer | 291890 0.3849% | $296,268.35 | 0 | 4 | |
| Hutson Nancy J | director | 93000 0.1226% | $94,395.00 | 5 | 0 | <0.0001% |
| Cagle Gerald D. | director | 23441 0.0309% | $23,792.62 | 4 | 1 | +5.28% |
| Humphries William D. | director | 5586 0.0074% | $5,669.79 | 1 | 0 | +50% |
| SHAFFER CHRISTY L | director | 4400 0.0058% | $4,466.00 | 3 | 0 | +7.86% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$49,091,668 | 110 | 13.11% | $74.29M | |
$2,600,095 | 110 | 13.50% | $75.75M | |
$155,580,641 | 77 | -24.21% | $82.5M | |
$329,102,560 | 42 | 30.96% | $75.32M | |
$542,300 | 40 | -14.44% | $78.02M | |
Clearside Biomedical, Inc. (CLSD) | $22,158,933 | 35 | 28.41% | $76.98M |
$26,678,853 | 21 | -5.95% | $81.77M | |
$1,602,584 | 20 | 15.26% | $72.1M | |
$1,239,833 | 16 | 53.23% | $72.59M | |
$70,704,995 | 14 | 67.19% | $81.68M | |
$73,968,137 | 12 | -34.52% | $77.08M | |
$15,724,108 | 9 | 124.63% | $74.96M | |
$13,043,783 | 8 | 732.82% | $81.14M | |
$4,895,542 | 8 | -11.85% | $83.84M | |
$32,684,649 | 8 | -15.84% | $73.18M | |
$141,999,928 | 6 | -34.00% | $72.47M | |
$18,186,879 | 4 | 49.41% | $80.53M | |
$30,000,002 | 1 | -24.63% | $81.68M | |
$4,030 | 1 | 9.14% | $75.52M |
CLSD Institutional Investors: Active Positions
| Increased Positions | 22 | +35.48% | 563,557 | +5.58% |
| Decreased Positions | 23 | -37.1% | 1M | -11.82% |
| New Positions | 10 | New | 309,340 | New |
| Sold Out Positions | 16 | Sold Out | 711,337 | Sold Out |
| Total Postitions | 61 | -1.61% | 9M | -6.23% |
CLSD Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $2,821.00 | 3.69% | 2.81M | -33,371 | -1.18% | 2024-12-31 |
| Carmignac Gestion | $1,943.00 | 2.54% | 1.93M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $882.00 | 1.16% | 877,647 | +73,692 | +9.17% | 2024-12-31 |
| Geode Capital Management, Llc | $768.00 | 1.01% | 764,058 | +32,672 | +4.47% | 2024-12-31 |
| Renaissance Technologies Llc | $725.00 | 0.95% | 721,789 | -23,100 | -3.1% | 2024-12-31 |
| First Manhattan Co. Llc. | $408.00 | 0.53% | 405,668 | -260,474 | -39.1% | 2024-12-31 |
| State Street Corp | $267.00 | 0.35% | 265,263 | +60,100 | +29.29% | 2024-12-31 |
| Bridgeway Capital Management, Llc | $256.00 | 0.34% | 255,000 | 0 | 0% | 2024-12-31 |
| Northern Trust Corp | $166.00 | 0.22% | 165,499 | +32,048 | +24.02% | 2024-12-31 |
| Ubs Group Ag | $146.00 | 0.19% | 145,118 | +145,118 | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.